RxDoctor Payments Data

Iyabo Daramola, MD

Internal Medicine · San Diego, CANPI 1851378236

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 101 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$229
  • Boehringer Ingelheim$118
  • Astellas Pharma US Inc$53
  • Novartis$41
  • Johnson & Johnson$33
  • plus $162 from 8 others

What the payments were for

  • Travel & lodging$30%
  • Food & beverage$1,998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$681,207
Medicare patients
302
Services billed
8,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide254$247,814
JanuviaSitagliptin Phosphate100$76,986
JardianceEmpagliflozin82$69,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$55,232
TrulicityDulaglutide41$52,854
RybelsusSemaglutide23$44,809
EliquisApixaban36$31,195
TradjentaLinagliptin53$26,809
Tresiba Flextouch U-200Insulin Degludec43$26,511
LinzessLinaclotide30$16,811
EntrestoSacubitril/Valsartan14$13,584
InvokanaCanagliflozin25$8,603
FarxigaDapagliflozin Propanediol11$8,362
GlyxambiEmpagliflozin/Linagliptin12$6,525
MovantikNaloxegol Oxalate15$6,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,365$292,623277 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$118$103,135147 claims
MerckJanuvia$19$76,986100 claims
Lilly USA, LLCTrulicity$229$52,85441 claims
AbbVieLinzess$22$16,81130 claims
NovartisEntresto$41$13,58414 claims
AstraZenecaFarxiga, Symbicort$31$10,75822 claims
Johnson & JohnsonInvokana$33$8,60325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →